A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Clinical Trial to Evaluate Efficacy and Safety of QLG1091 Versus Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Latest Information Update: 30 Mar 2026
At a glance
- Drugs QLG 1090 (Primary) ; Semaglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 30 Mar 2026 New trial record